<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095211</url>
  </required_header>
  <id_info>
    <org_study_id>Elderly St.Ingbert</org_study_id>
    <nct_id>NCT01095211</nct_id>
  </id_info>
  <brief_title>B-vitamins Treatment for Improvement of Cognitive Function</brief_title>
  <official_title>Effect of B-Vitamins on Cognitive Function in Elderly People</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saarland University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Geriatrische Rehaklinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saarland University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observation studies documented a correlation between plasma concentrations of homocysteine
      and cognitive decline with age. The study hypothesis was that high doses of B-vitamins (as
      effective homocysteine lowering treatment) can improve cognitive function in elderly people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We performed a treatment with therapeutic doses of B-vitamins (folic acid, cobalamin, vitamin
      B6) for 45 days. We collected blood and tested the concentrations of the metabolic markers in
      blood at start, 3 weeks later and at the end. Cognitive function was tested at start and at
      the end.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>baseline and 45 days later</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Cognitive Function</condition>
  <condition>Metabolic Improvements</condition>
  <arm_group>
    <arm_group_label>B-Vitamins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>folic acid, cobalamin, vitamin B6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>none of the vitamins (99.5% mannitol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B-vitamin complex</intervention_name>
    <description>5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily</description>
    <arm_group_label>B-Vitamins</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>no other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 65 years and glomerular filtration rate (GFR) &gt; 35 ml/min

        Exclusion Criteria:

          -  acute cancer or those who had coronary or cerebral event or thrombosis in the last 3
             months were not eligible for the study.

          -  furthermore, people who had dementia (mini-mental state-examination scores MMSE &lt; 15)

          -  those treated with B-vitamins

          -  those with renal insufficiency

          -  those receiving drugs that affect Hcy-metabolism (methotrexate, anti-epileptics,
             L-dopa) were not allowed to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rima Obeid</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Chemistry, University of Saarland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Eckert-</name>
      <address>
        <city>Sankt Ingbert</city>
        <state>Saarland</state>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <name_title>Dr. Eckert</name_title>
    <organization>Kreiskrankenhaus St. Ingbert GmbH</organization>
  </responsible_party>
  <keyword>folic acid</keyword>
  <keyword>homocysteine</keyword>
  <keyword>MMSE scores</keyword>
  <keyword>methyl malonic acid</keyword>
  <keyword>betaine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

